Upcoming Dividend • Jun 22
Upcoming dividend of JP¥18.00 per share Eligible shareholders must have bought the stock before 29 June 2026. Payment date: 04 September 2026. Payout ratio is a comfortable 73% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.9%). Lower than average of industry peers (3.9%). Ankündigung • Jun 13
Human Metabolome Technologies, Inc. to Report Fiscal Year 2026 Results on Aug 07, 2026 Human Metabolome Technologies, Inc. announced that they will report fiscal year 2026 results on Aug 07, 2026 Reported Earnings • May 17
Third quarter 2026 earnings released: EPS: JP¥21.76 (vs JP¥35.84 in 3Q 2025) Third quarter 2026 results: EPS: JP¥21.76 (down from JP¥35.84 in 3Q 2025). Revenue: JP¥448.0m (down 23% from 3Q 2025). Net income: JP¥122.0m (down 42% from 3Q 2025). Profit margin: 27% (down from 36% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. New Risk • Feb 16
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Dividend per share is over 5x cash flows per share. Dividend yield: 2.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Dividend is not well covered by cash flows (dividend per share is over 5x cash flows per share). Market cap is less than US$100m (JP¥4.28b market cap, or US$27.9m). Reported Earnings • Feb 14
Second quarter 2026 earnings released: EPS: JP¥24.79 (vs JP¥21.63 in 2Q 2025) Second quarter 2026 results: EPS: JP¥24.79 (up from JP¥21.63 in 2Q 2025). Revenue: JP¥467.0m (up 14% from 2Q 2025). Net income: JP¥140.0m (up 9.4% from 2Q 2025). Profit margin: 30% (down from 31% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year. Declared Dividend • Feb 14
Dividend of JP¥18.00 announced Shareholders will receive a dividend of JP¥18.00. Ex-date: 29th June 2026 Payment date: 4th September 2026 Dividend yield will be 2.5%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Feb 12
Human Metabolome Technologies, Inc. (TSE:6090) announces an Equity Buyback for 25,000 shares, representing 4.44% for ¥200 million. Human Metabolome Technologies, Inc. (TSE:6090) announces a share repurchase program. Under the program, the company will repurchase up to 25,000 shares, representing 4.44% of its issued share capital, for ¥200 million. The purpose of the program is to improve shareholder returns and capital efficiency. The program will expire on December 31, 2026. As of December 31, 2025, the company had 5,627,579 shares in issue (excluding treasury stock and 292,218 shares in treasury. Ankündigung • Nov 29
Human Metabolome Technologies, Inc. to Report Q2, 2026 Results on Feb 12, 2026 Human Metabolome Technologies, Inc. announced that they will report Q2, 2026 results on Feb 12, 2026 New Risk • Nov 15
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (JP¥3.74b market cap, or US$24.2m). Reported Earnings • Nov 15
First quarter 2026 earnings released: JP¥17.08 loss per share (vs JP¥5.92 loss in 1Q 2025) First quarter 2026 results: JP¥17.08 loss per share (further deteriorated from JP¥5.92 loss in 1Q 2025). Revenue: JP¥192.0m (down 30% from 1Q 2025). Net loss: JP¥97.0m (loss widened 177% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 4% per year. Ankündigung • Oct 02
Human Metabolome Technologies, Inc. to Report Q1, 2026 Results on Nov 12, 2025 Human Metabolome Technologies, Inc. announced that they will report Q1, 2026 results on Nov 12, 2025 Reported Earnings • Aug 10
Full year 2025 earnings released: EPS: JP¥43.59 (vs JP¥41.10 in FY 2024) Full year 2025 results: EPS: JP¥43.59 (up from JP¥41.10 in FY 2024). Revenue: JP¥1.46b (up 8.2% from FY 2024). Net income: JP¥256.0m (up 5.3% from FY 2024). Profit margin: 18% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year. Ankündigung • Aug 08
Human Metabolome Technologies, Inc., Annual General Meeting, Sep 19, 2025 Human Metabolome Technologies, Inc., Annual General Meeting, Sep 19, 2025. New Risk • Jul 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥4.36b market cap, or US$29.3m). Upcoming Dividend • Jun 20
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (4.0%). Lower than average of industry peers (3.0%). Ankündigung • Jun 07
Human Metabolome Technologies, Inc. to Report Fiscal Year 2025 Results on Aug 08, 2025 Human Metabolome Technologies, Inc. announced that they will report fiscal year 2025 results on Aug 08, 2025 Reported Earnings • May 19
Third quarter 2025 earnings released: EPS: JP¥35.84 (vs JP¥26.54 in 3Q 2024) Third quarter 2025 results: EPS: JP¥35.84 (up from JP¥26.54 in 3Q 2024). Revenue: JP¥582.0m (up 21% from 3Q 2024). Net income: JP¥211.0m (up 34% from 3Q 2024). Profit margin: 36% (up from 33% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year. Ankündigung • Mar 01
Human Metabolome Technologies, Inc. to Report Q3, 2025 Results on May 14, 2025 Human Metabolome Technologies, Inc. announced that they will report Q3, 2025 results on May 14, 2025 Declared Dividend • Feb 15
Dividend of JP¥15.00 announced Shareholders will receive a dividend of JP¥15.00. Ex-date: 27th June 2025 Payment date: 5th September 2025 Dividend yield will be 2.3%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 38% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Feb 13
Human Metabolome Technologies, Inc. (TSE:6090) announces an Equity Buyback for 130,000 shares, representing 2.2% for ¥100 million. Human Metabolome Technologies, Inc. (TSE:6090) announces a share repurchase program. Under the program, the company will repurchase up to 130,000 shares, representing 2.2% of its issued share capital, for ¥100 million. The purpose of the program is to improve shareholder returns and capital efficiency. The program will expire on December 31, 2025. As of December 31, 2024, the company had 5,919,653 shares in issue (excluding treasury stock and 144 shares in treasury. Ankündigung • Jan 17
Human Metabolome Technologies, Inc. to Report Q2, 2025 Results on Feb 13, 2025 Human Metabolome Technologies, Inc. announced that they will report Q2, 2025 results on Feb 13, 2025 Board Change • Oct 07
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Natsukari Hajime was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Oct 02
Human Metabolome Technologies, Inc. to Report Q1, 2025 Results on Nov 13, 2024 Human Metabolome Technologies, Inc. announced that they will report Q1, 2025 results on Nov 13, 2024 Ankündigung • Aug 09
Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024 Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to JP¥511, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 32% over the past three years. Buy Or Sell Opportunity • Aug 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to JP¥511. The fair value is estimated to be JP¥639, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company has become profitable. Upcoming Dividend • Jun 20
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 27 June 2024. Payment date: 09 September 2024. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.6%). Ankündigung • Jun 06
Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024 Human Metabolome Technologies, Inc. announced that they will report fiscal year 2024 results on Aug 09, 2024 Reported Earnings • May 21
Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023) Third quarter 2024 results: EPS: JP¥26.54 (up from JP¥26.07 in 3Q 2023). Revenue: JP¥483.0m (up 3.9% from 3Q 2023). Net income: JP¥157.0m (up 1.9% from 3Q 2023). Profit margin: 33% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Ankündigung • Mar 28
Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024 Human Metabolome Technologies, Inc. announced that they will report Q3, 2024 results on May 15, 2024 Reported Earnings • Feb 17
Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023) Second quarter 2024 results: EPS: JP¥18.43 (up from JP¥15.41 in 2Q 2023). Revenue: JP¥397.0m (up 14% from 2Q 2023). Net income: JP¥109.0m (up 20% from 2Q 2023). Profit margin: 28% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Declared Dividend • Feb 16
Dividend of JP¥15.00 announced Shareholders will receive a dividend of JP¥15.00. Ex-date: 27th June 2024 Payment date: 9th September 2024 Dividend yield will be 2.3%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is covered by both earnings (22% earnings payout ratio) and cash flows (53% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 71% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Nov 27
Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024 Human Metabolome Technologies, Inc. announced that they will report Q2, 2024 results on Feb 14, 2024 Reported Earnings • Nov 12
First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023) First quarter 2024 results: JP¥6.43 loss per share (further deteriorated from JP¥2.88 loss in 1Q 2023). Revenue: JP¥235.0m (down 10% from 1Q 2023). Net loss: JP¥38.0m (loss widened 124% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Ankündigung • Sep 28
Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023 Human Metabolome Technologies, Inc. announced that they will report Q1, 2024 final results on Nov 10, 2023 New Risk • Aug 16
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 47% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Market cap is less than US$100m (JP¥4.29b market cap, or US$29.5m). Reported Earnings • Aug 12
Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022) Full year 2023 results: EPS: JP¥48.27 (up from JP¥45.25 in FY 2022). Revenue: JP¥1.30b (up 6.2% from FY 2022). Net income: JP¥285.0m (up 6.7% from FY 2022). Profit margin: 22% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Ankündigung • Aug 12
Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023 Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023. Ankündigung • Jun 03
Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023 Human Metabolome Technologies, Inc. announced that they will report fiscal year 2023 results on Aug 10, 2023 Reported Earnings • May 17
Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022) Third quarter 2023 results: EPS: JP¥26.07 (down from JP¥33.73 in 3Q 2022). Revenue: JP¥465.0m (down 2.5% from 3Q 2022). Net income: JP¥154.0m (down 23% from 3Q 2022). Profit margin: 33% (down from 42% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 18
Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022) Second quarter 2023 results: EPS: JP¥15.41 (down from JP¥22.03 in 2Q 2022). Revenue: JP¥348.0m (down 3.3% from 2Q 2022). Net income: JP¥91.0m (down 30% from 2Q 2022). Profit margin: 26% (down from 36% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Ankündigung • Dec 24
Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023 Human Metabolome Technologies, Inc. announced that they will report Q2, 2023 results on Feb 14, 2023 Buying Opportunity • Dec 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 26%. The fair value is estimated to be JP¥833, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last year. Meanwhile, the company has become profitable. Reported Earnings • Nov 16
First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022) First quarter 2023 results: JP¥2.88 loss per share (improved from JP¥8.14 loss in 1Q 2022). Revenue: JP¥262.0m (up 51% from 1Q 2022). Net loss: JP¥17.0m (loss narrowed 65% from 1Q 2022). Reported Earnings • Nov 13
First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022) First quarter 2023 results: JP¥2.88 loss per share (improved from JP¥8.14 loss in 1Q 2022). Revenue: JP¥262.0m (up 51% from 1Q 2022). Net loss: JP¥17.0m (loss narrowed 65% from 1Q 2022). Ankündigung • Nov 12
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023 Human Metabolome Technologies, Inc. provided consolidated earnings guidance for the year ending June 2023. For the year, the company expects net sales of JPY 1,300 million, operating profit of JPY 240 million, profit attributable to owners of parent of JPY 270 million or JPY 45.76 per share basic. Valuation Update With 7 Day Price Move • Oct 31
Investor sentiment improved over the past week After last week's 17% share price gain to JP¥828, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 16x in the Life Sciences industry in Japan. Negligible returns to shareholders over past three years. Ankündigung • Sep 16
Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022 Human Metabolome Technologies, Inc. announced that they will report Q1, 2023 results on Nov 11, 2022 Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment improved over the past week After last week's 17% share price gain to JP¥959, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total returns to shareholders of 17% over the past three years. Reported Earnings • Aug 12
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: JP¥45.25 (up from JP¥9.84 in FY 2021). Revenue: JP¥1.22b (up 8.8% from FY 2021). Net income: JP¥267.0m (up 360% from FY 2021). Profit margin: 22% (up from 5.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 79%. Over the next year, revenue is forecast to grow 6.3%, compared to a 16% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 152% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Ankündigung • Aug 12
Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022 Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022. Ankündigung • Jul 30
Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity Human Metabolome Technologies, Inc. Common Stock will be deleted from OTC Equity effective from July 29, 2022, due to Inactive Security. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 16% share price gain to JP¥864, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years. Ankündigung • Jun 24
Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022 Human Metabolome Technologies, Inc. announced that they will report fiscal year 2022 results on Aug 10, 2022 Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improved over the past week After last week's 17% share price gain to JP¥720, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 22% over the past three years. Reported Earnings • May 19
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: EPS: JP¥33.73 (up from JP¥16.96 in 3Q 2021). Revenue: JP¥477.0m (up 23% from 3Q 2021). Net income: JP¥199.0m (up 99% from 3Q 2021). Profit margin: 42% (up from 26% in 3Q 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 5.6% compared to a 3.2% decline forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 138% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Ankündigung • May 15
Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022 Human Metabolome Technologies, Inc. provided earnings guidance for the full year ending June 2022. For the period, the company expected net sales of JPY 1,200 million, operating profit of JPY 150 million, profit attributable to owners of parent of JPY 170 million and basic earnings per share of JPY 28.81. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Junichi Matsuda was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • Apr 08
Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022 Human Metabolome Technologies, Inc. announced that they will report Q3, 2022 results on May 13, 2022 Reported Earnings • Feb 17
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: EPS: JP¥22.03 (up from JP¥4.92 in 2Q 2021). Revenue: JP¥360.0m (up 23% from 2Q 2021). Net income: JP¥130.0m (up 348% from 2Q 2021). Profit margin: 36% (up from 9.9% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 12% while the industry in Japan is not expected to grow. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Ankündigung • Feb 16
Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022 Human Metabolome Technologies, Inc. provided consolidated earnings guidance for the year ending June 30, 2022. For the year ending June 30, 2022, the company expects consolidated net sales to be JPY 1,200 million, operating profit to be JPY 120 million, profit attributable to owners of parent to be JPY 120 million and basic earnings per share to be JPY 20.34. Reported Earnings • Nov 15
First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2022 results: Revenue: JP¥173.0m (down 29% from 1Q 2021). Net loss: JP¥48.0m (loss widened 33% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Reported Earnings • May 15
Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥389.0m (up 211% from 3Q 2020). Net income: JP¥100.0m (up JP¥235.0m from 3Q 2020). Profit margin: 26% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 14
Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥292.0m (up 134% from 2Q 2020). Net income: JP¥29.0m (up JP¥164.0m from 2Q 2020). Profit margin: 9.9% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 26
New 90-day high: JP¥999 The company is up 1.0% from its price of JP¥989 on 28 October 2020. The Japanese market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 2.0% over the same period. Ankündigung • Dec 26
Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021 Human Metabolome Technologies, Inc. announced that they will report Q2, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Dec 17
New 90-day low: JP¥741 The company is down 37% from its price of JP¥1,170 on 18 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 16% over the same period. Is New 90 Day High Low • Dec 01
New 90-day low: JP¥860 The company is down 25% from its price of JP¥1,149 on 02 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period. Ankündigung • Sep 26
Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020 Human Metabolome Technologies, Inc. announced that they will report Q1, 2021 results on Nov 11, 2020 Ankündigung • Jun 29
Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020 Human Metabolome Technologies, Inc. announced that they will report fiscal year 2020 results on Aug 14, 2020 
